Overview

A Study to Investigate the Safety and Tolerability of TE-8105 in Overweight/Obese Participants Without Diabetes

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-06-06
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2a, first-in-human, prospective, open-label study to evaluate the safety, tolerability, PK, PD, and effect on body weight of TE-8105 in overweight/obese participants without diabetes. Study TE-8105-101 consists of 2 parts: Part A (single-ascending dose \[SAD\]) and Part B (multiple-ascending dose \[MAD\])
Phase:
PHASE1
Details
Lead Sponsor:
Immunwork, Inc.